Capricor Therapeutics Stock Surges on Oppenheimer Upgrade Amid FDA Review Hopes

By EC Assets · Published 25 August 2026

Capricor Therapeutics stock surged today following an upgrade by Oppenheimer. This market movement occurs after the company experienced a significant fair value reduction by analysts. Analysts lowered fair value estimates for Capricor Therapeutics from approximately US$49.44 to about US$4.38. Capricor Therapeutics shares more than doubled in premarket trading on Friday. This increase followed the company's announcement that the U.S. health regulator is willing to review new data on its experimental Duchenne muscular drug. Capricor Therapeutics stock had previously plunged 32% on a Friday after a trading halt. This decline occurred after Stat News reported that the head of the FDA unit for biologic drugs canceled an advisory meeting. Capricor Therapeutics announced a proposed public offering of common stock on December 04, 2025. The company later announced the pricing of a $150 million public offering of common stock on December 05, 2025. Capricor Therapeutics, Inc. develops transformative cell and exosome-based therapeutics. This article is intended for informational purposes only. It does not constitute investment advice.